MX2023012782A - Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares. - Google Patents

Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares.

Info

Publication number
MX2023012782A
MX2023012782A MX2023012782A MX2023012782A MX2023012782A MX 2023012782 A MX2023012782 A MX 2023012782A MX 2023012782 A MX2023012782 A MX 2023012782A MX 2023012782 A MX2023012782 A MX 2023012782A MX 2023012782 A MX2023012782 A MX 2023012782A
Authority
MX
Mexico
Prior art keywords
growth factor
eye diseases
treatment
factor compositions
compositions
Prior art date
Application number
MX2023012782A
Other languages
English (en)
Spanish (es)
Inventor
Piotr Bryla
Susan C Orr
A Clarke Atwell
Original Assignee
Claris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claris Biotherapeutics Inc filed Critical Claris Biotherapeutics Inc
Publication of MX2023012782A publication Critical patent/MX2023012782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2023012782A 2021-05-14 2022-05-13 Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares. MX2023012782A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163188816P 2021-05-14 2021-05-14
PCT/US2022/072302 WO2022241465A1 (en) 2021-05-14 2022-05-13 Compositions of growth factor for the treatment of eye disease

Publications (1)

Publication Number Publication Date
MX2023012782A true MX2023012782A (es) 2024-03-25

Family

ID=81756753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012782A MX2023012782A (es) 2021-05-14 2022-05-13 Composiciones de factor de crecimiento para el tratamiento de enfermedades oculares.

Country Status (12)

Country Link
US (1) US20230022990A1 (cg-RX-API-DMAC10.html)
EP (2) EP4337243A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518178A (cg-RX-API-DMAC10.html)
KR (1) KR20240035394A (cg-RX-API-DMAC10.html)
CN (1) CN117677394A (cg-RX-API-DMAC10.html)
AU (1) AU2022272740A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023022474A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218000A1 (cg-RX-API-DMAC10.html)
IL (1) IL308496A (cg-RX-API-DMAC10.html)
MX (1) MX2023012782A (cg-RX-API-DMAC10.html)
TW (1) TW202310868A (cg-RX-API-DMAC10.html)
WO (1) WO2022241465A1 (cg-RX-API-DMAC10.html)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5510329A (en) * 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
JP2000344680A (ja) * 1999-05-31 2000-12-12 Mitsubishi Chemicals Corp Ｈｇｆ含有医薬組成物
WO2004026244A2 (en) * 2002-09-18 2004-04-01 Emiliano Ghinelli Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US8895508B2 (en) * 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
KR102291913B1 (ko) * 2014-04-28 2021-08-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆ의 동결건조 제제
DK3192524T3 (da) 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
JP6929273B2 (ja) * 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116710568A (zh) * 2020-06-26 2023-09-05 特里福伊尔治疗公司 重组修饰成纤维细胞生长因子及其治疗用途

Also Published As

Publication number Publication date
IL308496A (en) 2024-01-01
CN117677394A (zh) 2024-03-08
US20230022990A1 (en) 2023-01-26
KR20240035394A (ko) 2024-03-15
AU2022272740A9 (en) 2023-11-09
JP2024518178A (ja) 2024-04-25
BR112023022474A2 (pt) 2024-01-09
WO2022241465A1 (en) 2022-11-17
TW202310868A (zh) 2023-03-16
CA3218000A1 (en) 2022-11-17
EP4574211A2 (en) 2025-06-25
EP4574211A3 (en) 2025-09-10
EP4337243A1 (en) 2024-03-20
AU2022272740A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
UY39049A (es) Composición para controlar las enfermedades de las plantas y método para controlar las enfermedades de las plantas
MX2021001558A (es) Inhibidores de itk de pirrolopirimidina.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
UY39048A (es) Composición para controlar las enfermedades de las plantas y método para controlar las enfermedades de las plantas
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
BR112019005226A2 (pt) sistema de cateter para tratar doenças vasculares e não vasculares
AR101740A1 (es) Terapia de combinación y composiciones
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CO2022000481A2 (es) Inhibidores de enzimas
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
CO2022014499A2 (es) Moduladores de nlrp3
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022000270A2 (es) Inhibidores de enzimas
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
BR112017025263A2 (pt) método para o tratamento de doença neurológica
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2021008941A (es) Moduladores gpr35.
ECSP23076552A (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
CO2024009582A2 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap/taz tead